Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma

被引:19
|
作者
Shimizu, Katsuhiko [1 ]
Okita, Riki [1 ]
Saisho, Shinsuke [1 ]
Maeda, Ai [1 ]
Nojima, Yuji [1 ]
Nakata, Masao [1 ]
机构
[1] Kawasaki Med Sch, Dept Gen Thorac Surg, 577 Matsushima, Kurashiki, Okayama 7010192, Japan
来源
CANCER MANAGEMENT AND RESEARCH | 2017年 / 9卷
关键词
non-small-cell lung cancer; tumor microenvironment; programmed cell death-1 ligand 1 (PD-L1); tumor-infiltrating CD8-positive T lymphocytes; cyclooxygenase-2 (Cox-2); CYCLOOXYGENASE-2; EXPRESSION; T-CELLS; CANCER REGISTRY; CHEMOTHERAPY; NIVOLUMAB; SURVIVAL; CLASSIFICATION; ASSOCIATION; RECURRENCE; DOCETAXEL;
D O I
10.2147/CMAR.S146897
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death-1 ligand 1 (PD-L1), tumor-infiltrating CD8-positive T lymphocytes (CD8-positive TILs), and cyclooxygenase-2 (Cox-2) have been used as prognostic tools in patients with lung adenocarcinoma. We conducted a retrospective review of data from 170 patients who had undergone pulmonary resection as an initial treatment for clinical T1-2 N0 lung adenocarcinoma. We then investigated the expressions of three biomarkers using immunohistochemical analyses and compared the expression levels with the clinicopathological characteristics and outcomes of the patients. Next, we classified the tumors into four groups based on the PD-L1 and CD8-positive TILs statuses and evaluated the prognostic significance of Cox-2 expression according to the tumor immune microenvironment classification. Tumors with positive PD-L1 expression levels had a significantly larger number of CD8-positive TILs than tumors with negative PD-L1 expression levels, whereas tumors with high Cox-2 expressions had significantly fewer CD8-positive TILs than tumors with low Cox-2 expressions. A multivariate analysis showed that histological subtype, nodal metastasis, CD8-positive TILs count, and PD-L1 expression were independent predictors of patient outcome. Using a classification based on the PD-L1 and CD8-positive TILs statuses, the outcomes of patients with a negative PD-L1 expression and a high CD8-positive TIL count were significantly better than those with other classifications. In patients with negative PD-L1 and low CD8-positive TILs, the rate of EGFR mutation was significantly higher than that in other classifications, and Cox-2 expression was a powerful predictor of outcome. Clinical and pathological features in conjunction with the tumor immune microenvironment classification indicate that lung adenocarcinoma should be divided into different subgroups for prognosis and treatment. Classification according to the PD-L1 and CD8-positive TILs statuses might enable the effects of Cox-2 inhibitor to be predicted.
引用
收藏
页码:741 / 750
页数:10
相关论文
共 50 条
  • [1] Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma
    Suleiman, Yaman
    Coppola, Domenico
    Zibadi, Sherma
    Dalia, Samir
    Juan, TzuHua
    Lee, Jae K.
    Malafa, Mokenge Peter
    Soliman, Hatem Hussein
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
    Nie, Hanxiao
    He, Tao
    Wang, Li
    Zhang, Ling
    ONCOTARGETS AND THERAPY, 2021, 14 : 1377 - 1385
  • [3] Prognostic Value of Cox-2 Expression Differs Depending on CD8+T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma
    Shimizu, K.
    Okita, R.
    Saisho, S.
    Maeda, A.
    Nojima, Y.
    Nakata, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2108 - S2108
  • [4] Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma
    Hu, Jie
    Toyozumi, Takeshi
    Murakami, Kentaro
    Endo, Satoshi
    Matsumoto, Yasunori
    Otsuka, Ryota
    Shiraishi, Tadashi
    Iida, Shinichiro
    Morishita, Hiroki
    Makiyama, Tenshi
    Nishioka, Yuri
    Uesato, Masaya
    Hayano, Koichi
    Nakano, Akira
    Matsubara, Hisahiro
    CANCER MEDICINE, 2024, 13 (17):
  • [5] Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma
    Wei, Li-Jun
    Wu, Zi-Yun
    Wu, Li-Yan
    Wu, Ying-Wen
    Liang, Hao-Yu
    Luo, Rong-Zhen
    Liu, Li-Li
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [6] Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor
    Lopes-Neto, Belarmino Eugenio
    Sousa Nunes-Pinheiro, Diana Celia
    Vale Carvalheira, Julio Gil
    Schmitt, Fernando
    Gartner, Maria de Fatima
    ACTA SCIENTIAE VETERINARIAE, 2021, 49
  • [7] PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
    Ameratunga, Malaka
    Asadi, Khashayar
    Lin, Xihui
    Walkiewicz, Marzena
    Murone, Carmel
    Knight, Simon
    Mitchell, Paul
    Boutros, Paul
    John, Thomas
    PLOS ONE, 2016, 11 (04):
  • [8] COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes
    Cecil, Denise L.
    Gad, Ekram A.
    Corulli, Lauren R.
    Drovetto, Nicholas
    Lubet, Ronald A.
    Disis, Mary L.
    CANCER PREVENTION RESEARCH, 2022, 15 (04) : 225 - 232
  • [9] PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases.
    Lu, Benjamin Y.
    Gupta, Richa
    Ribeiro, Matthew
    Stewart, Tyler
    Chiang, Veronica
    Contessa, Joseph N.
    Adeniran, Adebowale
    Kluger, Harriet M.
    Jilaveanu, Lucia
    Schalper, Kurt A.
    Goldberg, Sarah B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
    Yagi, Taisuke
    Baba, Yoshifumi
    Ishimoto, Takatsugu
    Iwatsuki, Masaaki
    Miyamoto, Yuji
    Yoshida, Naoya
    Watanabe, Masayuki
    Baba, Hideo
    ANNALS OF SURGERY, 2019, 269 (03) : 471 - 478